Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) CEO David Portnoy purchased 3,850 shares of Cryo-Cell International stock in a transaction dated Thursday, November 10th. The stock was acquired at an average price of $4.90 per share, for a total transaction of $18,865.00. Following the completion of the transaction, the chief executive officer now owns 117,012 shares in the company, valued at approximately $573,358.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
David Portnoy also recently made the following trade(s):
Get
Cryo-Cell International alerts:
- On Tuesday, November 8th, David Portnoy purchased 20,000 shares of Cryo-Cell International stock. The stock was acquired at an average price of $4.89 per share, for a total transaction of $97,800.00.
Cryo-Cell International Trading Down 3.6 %
Cryo-Cell International stock opened at $4.77 on Friday. The stock has a market cap of $40.64 million, a price-to-earnings ratio of 33.00 and a beta of 0.35. The company's 50-day moving average price is $5.83 and its two-hundred day moving average price is $5.96. Cryo-Cell International, Inc. has a 52 week low of $4.68 and a 52 week high of $14.00.
Cryo-Cell International (OTCMKTS:CCEL – Get Rating) last released its earnings results on Friday, October 14th. The company reported $0.06 EPS for the quarter. The firm had revenue of $7.70 million for the quarter. Cryo-Cell International had a net
margin of 4.34% and a return on equity of 49.62%.
Cryo-Cell International Dividend Announcement
The business also recently announced a dividend, which was paid on Friday, September 9th. Shareholders of record on Friday, September 2nd were paid a dividend of $0.90 per share. The ex-dividend date was Thursday, September 1st.
Wall Street Analysts Forecast Growth
Separately, Maxim Group began coverage on shares of Cryo-Cell International in a research report on Monday, August 29th. They issued a "buy" rating and a $12.00 price objective on the stock.
Hedge Funds Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV lifted its holdings in Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,135 shares of the company's stock after purchasing an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned about 1.47% of Cryo-Cell International worth $732,000 at the end of the most recent reporting period. Institutional investors own 9.01% of the company's stock.
About Cryo-Cell International
(Get Rating)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
Recommended Stories
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
